Samsrita Labs Ltd — Board Meeting, 25-10-2025: Board Meeting
25-10-2025 | 05:22 pm
25-10-2025 | 05:22 pm
Samsrita Labs board approved Q2/H1 financial results, reporting a loss of ₹4.94 Cr. The company purchased a cancer drug patent for ₹2.36 Cr and acquired a 28.62% stake in QROPS Advisory Services via share swap, now an associate.
No comments yet. Be the first to comment!
